

Docket No.: TJU0001-107
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

In the Claims:

1-22. (Canceled)

23. (Currently Amended) A pharmaceutical composition comprising:

- a) a ST receptor binding ligand; and,
- b) a non-peptide radiostable active agent; and,
- c) a pharmaceutical carrier or diluent.

24. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide.

25. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

26. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

27. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

28. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is a therapeutic agent.

Docket No.: TJU0001-107
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

29. (Canceled)

30. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

31. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is 5-fluorouracil.

32. (Currently Amended) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives, ~~trememon~~, ~~ricin~~, ~~ricin A chain~~, ~~Pseudomonas exotoxin~~, ~~diphtheria toxin~~, ~~Clostridium perfringens phospholipase C~~, ~~bovine pancreatic ribonuclease~~, ~~pokeweed antiviral protein~~, ~~abrin~~, ~~abrin A chain~~, ~~cobra venom factor~~, ~~golonin~~, ~~saporin~~, ~~modocin~~, ~~viscumin~~, ~~volkensin~~, ~~alkaline phosphatase~~, ~~nitroimidazole~~, ~~metronidazole~~ and ~~misonidazole~~.

33. (Previously presented) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

Docket No.: TJU0001-107
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

34. (Previously presented) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

35. (Canceled)

36. (Previously presented) The pharmaceutical composition of claim 32 wherein said active agent is 5-fluorouracil.

37. (Canceled)

38. (Currently Amended) The pharmaceutical composition of claim 33 37 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

39. (Currently Amended) The pharmaceutical composition of claim 33 37 wherein said active agent is 5-fluorouracil.

40. (Previously presented) The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

41. (Previously presented) The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is an injectable pharmaceutical composition.

42. (Currently Amended) A The pharmaceutical composition comprising:

- a) a ST receptor binding ligand;
- b) a radiostable active agent; and
- c) a pharmaceutical carrier or diluent;

of claim 23 wherein said pharmaceutical composition is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome.

Docket No.: TJU0001-107
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

43. (Previously presented) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, treimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

44. (Previously presented) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 said the active agent is 5-fluorouracil.

45. (New) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

46. (New) The pharmaceutical composition of claim 42 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, treimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein,

Docket No.: TJU0001-107
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

47. (New) The pharmaceutical composition of claim 42 wherein the active agent is a non-peptide.